OpGen Reports $4 Million Revenue Surge and $3.51 Million Net Income in Strategic Shift to Financial Services

OpGen, Inc. reported significant financial changes in its latest 10-Q filing for the quarter ending June 30, 2025, reflecting a strategic pivot from its previous operations in molecular diagnostics to a focus on financial services and technology. The company generated total revenue of $4 million during the second quarter, a substantial increase from $28,000 in the same period last year. This revenue was exclusively derived from listing sponsorship services, marking a complete transition away from product sales and laboratory services, which had previously contributed to its revenue streams.

The company's operating expenses for the quarter decreased by approximately 62% to $597,225, down from $1.58 million in the prior year. This reduction was primarily due to the scaling down of legacy operations and a strategic shift in business focus. Notably, there were no costs associated with product sales or services, as the company has ceased its previous product lines. General and administrative expenses also saw a significant decline, reflecting the company's efforts to streamline operations and reduce overhead costs.

OpGen's net income for the quarter was reported at $3.51 million, a stark contrast to a net loss of $1.58 million in the same quarter of 2024. This turnaround was attributed to the successful completion of performance obligations under its new business model, which includes consultancy services for companies seeking to list their securities. The earnings per share for the quarter were $0.35, compared to a loss of $1.18 per share in the previous year.

In terms of operational developments, OpGen has undergone a significant organizational restructuring, including the deconsolidation of its subsidiaries, Curetis and Ares Genetics, following their insolvency filings in late 2023. The company has since focused on its wholly-owned subsidiary, CapForce International Holdings Ltd., which is positioned to offer financial technology services and listing sponsorship. As of June 30, 2025, OpGen had cash and cash equivalents of approximately $831,634, down from $1.31 million at the end of 2024, indicating a need for continued financing to support its operations.

Looking ahead, OpGen plans to fund its operations primarily through financing arrangements with AEI Capital Ltd., its controlling shareholder. The company has the right to sell up to $7 million in common stock to AEI Capital Ltd. by the end of 2025, which it anticipates will provide necessary liquidity as it continues to navigate its transition into the financial services sector. The company remains committed to exploring strategic opportunities while managing its operational costs effectively.